SEC Form 4Coverage since May 21, 2026
$BCAX insider trading
Over the last 12 months, Bicara Therapeutics insiders reported no purchases and 4 sales totaling $2.1M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.1M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $BCAX · 12Mvia TradingView
Top insiders · 12m
Hyep IvanChief Financial Officer2× · $996K
Mazumdar ClaireChief Executive Officer1× · $284K
Cohlhepp RyanPresident and COO1× · $833K
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Mazumdar ClaireChief Executive Officer · O·D | ▼ Sale | 10,000 | $28.42 | $284K | -2.7% | plan · 2 tranches |
| Jul 9, 2026 | Cohlhepp RyanPresident and COO · O·D | ▼ Sale | 28,750 | $28.98 | $833K | -13.7% | plan · 4 tranches |
| Jul 8, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 28,000 | $28.85 | $808K | -17.7% | plan · 3 tranches |
| May 21, 2026 | Hyep IvanChief Financial Officer · O | ▼ Sale | 9,200 | $20.42 | $188K | -6% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BCAX feed.